ScholarIQanswers from OpenAlex

Blood platelets and sepsis pathophysiology: A new therapeutic prospect in critical ill patients?

PaperCitations, authors & open-access status

Blood platelets and sepsis pathophysiology: A new therapeutic prospect in critical ill patients? is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Blood platelets and sepsis pathophysiology: A new therapeutic prospect in critical ill patients? have?

ScholarIQcitation count

Blood platelets and sepsis pathophysiology: A new therapeutic prospect in critical ill patients? has 206 citations in the OpenAlex counts ScholarIQ stores.

When was Blood platelets and sepsis pathophysiology: A new therapeutic prospect in critical ill patients? published?

ScholarIQyear

Blood platelets and sepsis pathophysiology: A new therapeutic prospect in critical ill patients? has 2017 year in the ScholarIQ index.

What is the open-access status of Blood platelets and sepsis pathophysiology: A new therapeutic prospect in critical ill patients??

ScholarIQoa status

Blood platelets and sepsis pathophysiology: A new therapeutic prospect in critical ill patients? has gold oa status in the ScholarIQ index.

What is the DOI of Blood platelets and sepsis pathophysiology: A new therapeutic prospect in critical ill patients??

ScholarIQdoi

The DOI for Blood platelets and sepsis pathophysiology: A new therapeutic prospect in critical ill patients? is on the source record.

What is the PMID of Blood platelets and sepsis pathophysiology: A new therapeutic prospect in critical ill patients??

ScholarIQpmid

The PMID for Blood platelets and sepsis pathophysiology: A new therapeutic prospect in critical ill patients? is on the source record.

What is the OpenAlex record for Blood platelets and sepsis pathophysiology: A new therapeutic prospect in critical ill patients??

ScholarIQopenalex

The OpenAlex for Blood platelets and sepsis pathophysiology: A new therapeutic prospect in critical ill patients? is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial